Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Intangibles (2017 - 2025)

Kiora Pharmaceuticals' Intangibles history spans 9 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Intangibles fell 69.15% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 69.15%, while the annual FY2025 figure was $2.1 million, 69.15% down from the prior year.
  • Intangibles reached $2.1 million in Q4 2025 per KPRX's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $10.8 million in Q4 2021 to a low of $2.1 million in Q4 2025.
  • Average Intangibles over 5 years is $8.7 million, with a median of $8.8 million recorded in 2023.
  • Peak YoY movement for Intangibles: skyrocketed 148.23% in 2021, then crashed 69.15% in 2025.
  • A 5-year view of Intangibles shows it stood at $10.8 million in 2021, then fell by 0.17% to $10.7 million in 2022, then dropped by 18.01% to $8.8 million in 2023, then dropped by 24.13% to $6.7 million in 2024, then plummeted by 69.15% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Intangibles are $2.1 million (Q4 2025), $6.7 million (Q3 2025), and $6.7 million (Q2 2025).